Aucta is a company creating better products of proven molecules.
Our corporate strategy is to focus on proven molecule, use 505(b)(2) regulatory pathway, through innovation, creating new therapeutics, with lower scientific risk and meet unmet medical needs in attractive market.
Aucta Pharmaceuticals is a new drug product development company focusing on branded 505b2 new product development. Aucta adopts a branded/generic hybrid model, generating both near term product revenue and mid/long term investment return, it aims to become a significant specialty pharma player in the U.S. and China market place. We focus on improved dosage forms for patients with a therapeutic focus in Pediatrics, CNS and Dermatology area.